Post COVID-19 burden: focus on the short-term condition.

The catastrophic pandemic of the coronavirus disease 2019 (COVID-19) has caused serious harm to human life and global social economy. As of June 13, 2022, there were more than 530 million confirmed cases of COVID19 and over 6.3 million deaths[1]. During the past 2 years, global studies on prevention and therapies for COVID19 have achieved a series of promising findings, including antiviral drugs (Remdesivir, Molnupiravir, Paxlovid) and monoclonal antibodies (Bamlanivimab and Etesevimab, Sotrovimab, Casirivimab and Imdevimab)[2]. World Health Organization (WHO) has validated 11 vaccines for the emergency use listing (EUL)[3]. As of June 13, 2022, more than 11.9 billion vaccine doses have been administered worldwide[1]. In China, integrated using of traditional Chinese medicine (TCM) and Western medicine is one of the highlights in fighting COVID-19. “Three formulations and three drugs” (Jinhua Qinggan granules, Lianhua Qingwen capsule, Xuebijing injection, and Qingfei Paidu decoction, Huashi Baidu decoction, Xuanfei Baidu decoction) have been approved by National Medical Products Administration (NMPA) as new drugs or adding indications for COVID-19[4]. The new drugs and vaccines had become effective weapons in the fight against the pandemic.